Literature DB >> 10953847

The technique of nasendoscopy in the evaluation of nasolacrimal duct obstruction in children.

B Ram1, C W Barras, P S White, C J MacEwen, J D Young.   

Abstract

Epiphora in infancy is most commonly the result of failure of canalisation of the nasolacrimal duct and most cases resolve spontaneously within 12 months. Lacrimal probing is the standard operative treatment when conservative expectant management fails. While this carries a high success rate, it does not reliably localise the site of obstruction, can create a false passage and may induce traumatic stenosis in the lacrimal passages. Nasendoscopy in conjunction with the lacrimal probing overcomes these problems as the procedure is performed under direct vision. The precise site of opening of the nasolacrimal duct is ascertained, the nature of obstruction established and the risks of false passage creation minimised. We report this technique of endoscopic assessment of lacrimal probing, and the outcome results of twenty such procedures performed on thirteen children.

Entities:  

Mesh:

Year:  2000        PMID: 10953847

Source DB:  PubMed          Journal:  Rhinology        ISSN: 0300-0729            Impact factor:   3.681


  4 in total

1.  Value of nasal endoscopy and probing in the diagnosis and management of children with congenital epiphora.

Authors:  C J MacEwen; J D Young; C W Barras; B Ram; P S White
Journal:  Br J Ophthalmol       Date:  2001-03       Impact factor: 4.638

2.  Management of childhood epiphora.

Authors:  J E Marr; A Drake-Lee; H E Willshaw
Journal:  Br J Ophthalmol       Date:  2005-09       Impact factor: 4.638

3.  Congenital dacryocystocele: diagnosis and treatment.

Authors:  S Cavazza; G L Laffi; L Lodi; G Tassinari; D Dall'Olio
Journal:  Acta Otorhinolaryngol Ital       Date:  2008-12       Impact factor: 2.124

4.  Urgent bilateral endoscopic marsupialization for respiratory distress due to bilateral dacryocystitis in a newborn.

Authors:  Hochang Kim; Jongyeop Park; Jaeho Jang; Junwoo Chun
Journal:  J Craniofac Surg       Date:  2014-05       Impact factor: 1.046

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.